zasocitinib   Click here for help

GtoPdb Ligand ID: 12155

Synonyms: compound I-908 [US20190256519A1] | NDI-034858 | NDI034858 | TAK-279 | TAK279
PDB Ligand Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: NDI-034858 is an orally bioavailable TYK2-selective inhibitor. Its chemical structure was revealed during the first disclosures session at the 2022 ACS meeting in Chicago. NDI-034858 is one of the compounds (specifically I-908) claimed in patent US20190256519A1 [3]. The chemical structure is identical to that for the INN zasocitinib, and the name-to-structure was formally disclosed in 2026 [4].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 3
Rotatable bonds 8
Topological polar surface area 126.95
Molecular weight 460.2
XLogP 2.78
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CO[C@@H]1CC[C@H]1NC(=O)c1cnn2c1nc(Nc1cccn(c1=O)c1ccccn1)cc2NC
Isomeric SMILES CNc1cc(nc2c(cnn12)C(=O)N[C@@H]1CC[C@H]1OC)Nc1cccn(c1=O)c1ccccn1
InChI InChI=1S/C23H24N8O3/c1-24-20-12-18(27-16-6-5-11-30(23(16)33)19-7-3-4-10-25-19)29-21-14(13-26-31(20)21)22(32)28-15-8-9-17(15)34-2/h3-7,10-13,15,17,24H,8-9H2,1-2H3,(H,27,29)(H,28,32)/t15-,17-/m1/s1
InChI Key BWINBHTTZLVXGT-NVXWUHKLSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Elbuluk N, Armstrong AW, Vender R, Bhutani T, Green L, Ferris LK, Laquer V, Moore A, Weisman J, Zhang W et al.. (2026)
Zasocitinib (TAK-279), a Highly Selective Oral TYK2 Inhibitor, Demonstrates Skin Clearance in Patients with Moderate-to-Severe Plaque Psoriasis: Post Hoc Analyses of a Randomized Phase IIb Trial.
Dermatol Ther (Heidelb), 16 (6): 3215-3234. [PMID:42143206]
2. Leit S, Greenwood JR, Mondal S, Carriero S, Dahlgren M, Harriman GC, Kennedy-Smith JJ, Kapeller R, Lawson JP, Romero DL et al.. (2022)
Potent and selective TYK2-JH1 inhibitors highly efficacious in rodent model of psoriasis.
Bioorg Med Chem Lett, 73: 128891. [PMID:35842205]
3. Masse CE, Greenwood JR, Mondal S, Cowen SD, McLean TH. (2019)
Tyk2 inhibitors and uses thereof.
Patent number: US20190256519A1. Assignee: Nimbus Discovery Inc. Priority date: 28/07/2017. Publication date: 22/08/2019.
4. Mehrotra S, Sano Y, Halkowycz P, Wilson E, Durairaj C, Kong KF, Xia G, Dunbar F, Spector T, Heap GA et al.. (2026)
Pharmacological Characterization of Zasocitinib (TAK-279): An Oral, Highly Selective, and Potent Allosteric TYK2 Inhibitor.
J Invest Dermatol, 146 (1): 214-222.e7. [PMID:40441292]